企業概要
Evolus, Inc. operates as a performance beauty company that delivers products within the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The enterprise specifically offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation designed for the temporary improvement in the appearance of moderate facial lines. This business falls under the healthcare sector, specifically within the industry of drug manufacturers focused on specialty and generic pharmaceuticals, which implies a reliance on regulatory approvals and specialized distribution channels. The company's current market capitalization stands at $275.85 million, supported by an annual revenue of $297.18 million and an employee base of 334 individuals. These valuation and revenue figures suggest the company occupies a niche position in the aesthetic medicine landscape, balancing a specialized product portfolio with a relatively lean operational workforce to maintain focus on its core therapeutic offerings in international markets.
財務健全性
Evolus, Inc. reported a trailing twelve-month revenue of $297.18 million, yet recorded a net income of -$51.64 million and an EBITDA of -$30.09 million during the same period. The substantial gap between the positive revenue figure and the negative net income reveals a significant cost structure burden, likely driven by research and development expenditures, manufacturing costs, or operational expenses that exceed gross profits. The company generated free cash flow of -$26.69 million, indicating a current cash outflow that limits immediate financial flexibility and suggests that operating cash generation is insufficient to cover capital expenditures and working capital requirements. In terms of profitability margins, the gross margin is 66.3%, reflecting a healthy markup on the sale of its botulinum toxin products, while the operating margin stands at -0.3% and the profit margin is -17.4%, highlighting that fixed costs are eroding overall profitability. On the balance sheet, the company holds $53.83 million in cash against total debt of $155.00 million, and the debt-to-equity ratio is listed as N/A, indicating a highly leveraged position where liabilities significantly outweigh liquid assets. The current ratio is 1.90, which indicates that the company possesses 1.90 dollars in current assets for every dollar of current liabilities, providing a moderate buffer against short-term liquidity pressures despite the net debt situation. Furthermore, the return on equity is N/A and the return on assets is -10.3%, metrics that collectively reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
バリュエーション評価
The trailing P/E ratio is N/A due to the negative net income, whereas the forward P/E is 17.67, implying that the market is pricing in significant expected earnings growth that will turn the company profitable in the near future. The price-to-book ratio is -11.94, a negative figure that indicates the company's market capitalization is valued below its book value, a common scenario for biotech firms with high intangible assets or pending clinical trials that are not fully reflected on the balance sheet. Additionally, the price-to-sales ratio is 0.93 and the EV/EBITDA is -12.53, suggesting that investors are valuing the company primarily on its revenue generation potential rather than current earnings power or enterprise value multiples. The stock has exhibited a trading range with a 52-week high of $12.28 and a 52-week low of $3.86, meaning the current price sits below the recent peak but significantly above the annual trough, reflecting recent market volatility. The beta is 1.00, which indicates that the stock's price volatility moves in tandem with the broader market, lacking the defensive characteristics of lower beta stocks or the aggressive amplification of higher beta equities.
Growth & Income
Evolus, Inc. demonstrated a revenue growth year-over-year of 14.4%, while the earnings growth year-over-year is N/A due to the recent loss, implying that top-line expansion is occurring independently of immediate profitability improvements. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm retains all of its earnings to fund operations, research, and potential future growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for specialty drug manufacturers in the developmental or early commercialization phase where capital allocation toward product expansion takes precedence over income distribution. Overall, the growth and income profile is characterized by strong revenue expansion accompanied by a lack of current profitability and no dividend distribution, positioning the equity as a speculative growth play dependent on future margin expansion and successful commercialization of its aesthetic products.